EQ
Equillium, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.24
+4.20%Oct 6, 2026, 20:05 UTC
Equillium, Inc. announced a poster presentation of new preclinical data on EQ504 at the 50th Anniversary Equillium, Inc..
Source:Oct 5, 2026, 20:05 UTC
Equillium received Australian regulatory clearance to initiate a first-in-human clinical trial of EQ504, with dosing planned to begin by early November 2026.
Source: